Acerus Pharmaceuticals (OTCMKTS:TRLPF) Reaches New 1-Year High at $2.20

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPFGet Rating)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $2.20 and last traded at $2.20, with a volume of 109 shares changing hands. The stock had previously closed at $3.37.

The company has a fifty day moving average of $2.20 and a two-hundred day moving average of $0.80. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.64.

About Acerus Pharmaceuticals (OTCMKTS:TRLPF)

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia.

See Also

Receive News & Ratings for Acerus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acerus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.